GO:1901796 regulation of signal transduction by p53 class mediator: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1901796 describes any process that modulates the frequency, rate or extent of signal transduction by a p53 class mediator.
• The p53 class mediator includes the tumor suppressor p53 (TP53) and its family members, which coordinate cellular responses to stress.
• This regulatory process is central to DNA damage responses, apoptosis, cell cycle arrest, and senescence.
• Dysregulation of p53 signaling is implicated in cancer, inflammatory diseases, and developmental disorders.
• Key genes involved include TP53, MDM2, CDKN1A, BAX, and NFKB1, among others.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) are essential to dissect this pathway.
Description
The Gene Ontology term GO:1901796, regulation of signal transduction by p53 class mediator, defines any process that modulates the frequency, rate or extent of signal transduction by a p53 class mediator. This term captures the intricate regulatory layers that control how p53 and its family members transmit signals in response to cellular stress, including DNA damage, oncogenic activation, and ribosomal stress. Understanding this regulation is fundamental because p53 signaling is a critical barrier against tumorigenesis and a key determinant of cell fate. The p53 class mediator is not a single protein but a network of factors that include p53 itself, its upstream regulators such as MDM2, and downstream effectors like CDKN1A and BAX. These components work together to orchestrate transcriptional programs that lead to cell cycle arrest, apoptosis, or senescence. Moreover, crosstalk with other signaling pathways, such as NF-kB, adds another layer of complexity. Research into GO:1901796 has broad implications for cancer biology, neurobiology, and regenerative medicine. For instance, the regulation of p53 signaling is critical for neural stem cell function and neuronal progenitor maintenance. In cancer, therapeutic strategies often aim to restore or modulate p53 activity, making this term a focal point for drug discovery. Thus, a detailed understanding of the regulatory mechanisms encapsulated by GO:1901796 is essential for both basic researchers and translational scientists.
regulation of signal transduction by p53 class mediator At A Glance
| GO ID | GO:1901796 |
|---|---|
| GO term | regulation of signal transduction by p53 class mediator |
| Ontology | biological_process |
| Synonym | none |
| Major function | Modulates the frequency, rate or extent of signal transduction by p53 class mediator |
| Related genes | TP53, MDM2, CDKN1A, BAX, NFKB1, etc. |
| Associated diseases | Cancer, inflammatory diseases, developmental disorders |
| Research methods | CRISPR knockout, point mutation, knock-in, overexpression, RNA-seq, proteomics |
What Is GO:1901796?
GO:1901796, regulation of signal transduction by p53 class mediator, is a biological process that encompasses any mechanism that changes the frequency, rate, or extent of signal transduction mediated by proteins of the p53 class. This includes positive and negative regulation at multiple levels, such as post-translational modifications of p53, modulation of its stability, and interactions with other signaling pathways.
Why Is regulation of signal transduction by p53 class mediator Important in Cell Biology?
GO:1901796 is critically important because the p53 signaling pathway is a central node in cellular stress responses, and its dysregulation is a hallmark of many human diseases, particularly cancer. The regulation of this pathway determines whether a cell survives, arrests, or undergoes apoptosis, making it a key target for therapeutic intervention. Additionally, p53 signaling intersects with other major pathways such as NF-kB, influencing inflammation and immune responses. Therefore, understanding the regulatory mechanisms of p53 signal transduction is essential for developing novel treatments for cancer, neurodegenerative diseases, and other conditions.
• p53 signaling is a major tumor suppressor pathway; its regulation is frequently altered in cancer.
• Regulation of p53 signal transduction determines cell fate decisions (survival, arrest, apoptosis).
• Crosstalk between p53 and NF-kB pathways modulates inflammation and cancer progression.
• p53 signaling is essential for neural stem cell maintenance and neurogenesis.
• Dysregulation of p53 signaling is implicated in developmental disorders and premature aging.
• The pathway is a target for chemotherapeutic and radiotherapeutic interventions.
• Understanding its regulation aids in designing personalized cancer therapies.
• p53 signaling is involved in the response to ribosomal stress and nucleolar surveillance.
• MicroRNAs and other non-coding RNAs regulate p53 signaling, adding complexity.
• Mycoplasma infections can modulate p53/NF-kB signaling, linking infection to cancer.
What Happens During regulation of signal transduction by p53 class mediator?
Upstream stress signals and p53 activation
In simple terms: When a cell experiences stress like DNA damage, it activates p53 to trigger protective responses.
Various cellular stresses, including DNA damage, oncogene activation, and ribosomal stress, lead to the activation of p53 class mediators. This activation often involves post-translational modifications such as phosphorylation and acetylation, which stabilize p53 and enhance its transcriptional activity. For example, the nucleolar surveillance pathway contributes to p53 stabilization under ribosomal stress. These initial events are crucial for initiating the signal transduction cascade that is the subject of GO:1901796.
Regulation of p53 stability and activity
In simple terms: The amount and activity of p53 are tightly controlled by other proteins that can either degrade it or modify it.
The stability of p53 is primarily regulated by its interaction with MDM2, an E3 ubiquitin ligase that targets p53 for degradation. Under stress, this interaction is disrupted, allowing p53 to accumulate. Additionally, various kinases and acetyltransferases modify p53 to modulate its DNA-binding and transcriptional activities. This regulation ensures that p53 signaling is transient and reversible, preventing unwanted cell death or growth arrest.
Transcriptional and non-transcriptional effector programs
In simple terms: Active p53 turns on specific genes that carry out its functions, and also interacts directly with other proteins.
Once stabilized, p53 functions as a transcription factor to activate target genes such as CDKN1A (p21), which induces cell cycle arrest, and BAX, which promotes apoptosis. Beyond transcription, p53 can also interact with other proteins in the cytoplasm and mitochondria to directly trigger apoptosis. These effector programs are the ultimate output of p53 signal transduction and are subject to regulation by various cofactors and post-translational modifications.
Crosstalk with other signaling pathways
In simple terms: p53 signaling communicates with other pathways like NF-kB, affecting inflammation and immune responses.
The p53 pathway is not isolated; it engages in extensive crosstalk with other signaling cascades, notably the NF-kB pathway. For instance, p53 and NF-kB can mutually antagonize or cooperate depending on the context, influencing cell survival and inflammation. Mycoplasma infection has been shown to modulate host responses via p53/NF-kB signaling, highlighting the interplay between infection and these pathways. Such crosstalk is a key aspect of the regulation of p53 signal transduction (GO:1901796).
Key Genes Involved in GO:1901796 regulation of signal transduction by p53 class mediator
The following genes and proteins are central to the regulation of signal transduction by p53 class mediator (GO:1901796).
| Gene | Major Role | Research Relevance |
|---|---|---|
| TP53 | Tumor suppressor, transcription factor, central mediator | Most frequently mutated gene in cancer; key target for therapy |
| MDM2 | E3 ubiquitin ligase, negative regulator of p53 | Amplified in cancers; target for small molecule inhibitors |
| CDKN1A | p21, cyclin-dependent kinase inhibitor, mediates cell cycle arrest | Downstream effector of p53; biomarker of p53 activity |
| BAX | Pro-apoptotic Bcl-2 family member | Mediates p53-dependent apoptosis; prognostic marker |
| NFKB1 | NF-kB subunit, crosstalk with p53 | Inflammation and cancer; modulates p53 signaling |
| ATM | DNA damage sensor kinase, activates p53 | Mutations cause ataxia-telangiectasia; target for radiosensitization |
| CHEK2 | Checkpoint kinase, phosphorylates p53 | Variants associated with cancer risk |
| MDM4 | MDM2 homolog, inhibits p53 | Amplified in tumors; potential drug target |
| EP300 | Histone acetyltransferase, acetylates p53 | Enhances p53 transcriptional activity |
| CREBBP | Acetyltransferase, coactivator of p53 | Mutations in Rubinstein-Taybi syndrome |
| SIRT1 | Deacetylase, regulates p53 stability | Modulates aging and cancer |
| HIPK2 | Kinase, phosphorylates p53 at Ser46 | Promotes apoptosis; downregulated in tumors |
| PIN1 | Peptidyl-prolyl isomerase, stabilizes p53 | Overexpressed in cancers; target for inhibition |
| TP53BP1 | DNA damage response protein, interacts with p53 | Involved in DNA repair and checkpoint control |
| RPL5 | Ribosomal protein, triggers nucleolar stress | Implicated in ribosomopathies and p53 activation |
| RPL11 | Ribosomal protein, binds MDM2 | Mediates p53 stabilization upon ribosomal stress |
| NPM1 | Nucleophosmin, regulates p53 stability | Mutated in leukemia; interacts with p53 |
| MYC | Oncogene, activates p53 via ARF | Drives proliferation; crosstalk with p53 |
How Is regulation of signal transduction by p53 class mediator Regulated?
The regulation of p53 signal transduction (GO:1901796) is itself subject to multiple layers of control. Upstream kinases such as ATM and CHEK2 phosphorylate p53 in response to DNA damage, while MDM2 and MDM4 provide negative feedback by promoting p53 degradation. Ribosomal stress activates the nucleolar surveillance pathway, leading to p53 stabilization through ribosomal proteins like RPL5 and RPL11. Additionally, microRNAs can modulate p53 signaling by targeting components of the pathway. Crosstalk with NF-kB adds another regulatory layer, where the balance between p53 and NF-kB activities influences cell fate. These regulatory mechanisms ensure that p53 signaling is appropriately tuned to the cellular context.
regulation of signal transduction by p53 class mediator and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TP53 | Cancer (Li-Fraumeni syndrome, sporadic tumors) | TP53 knockout or point mutant cell lines (e.g., HCT116 p53-/-) |
| MDM2 | Cancer (amplification in sarcomas, gliomas) | MDM2 overexpression or knockout models |
| NFKB1 | Inflammation and cancer | NFKB1 knockout or reporter models |
| RPL5 | Diamond-Blackfan anemia | RPL5 knockdown or knockout in hematopoietic cells |
| ATM | Ataxia-telangiectasia | ATM knockout cell lines and mouse models |
Cancer
Dysregulation of p53 signal transduction is a hallmark of cancer. TP53 is the most frequently mutated gene in human cancers, and mutations often abrogate its tumor suppressor function. Even when TP53 is wild-type, its pathway can be inactivated by overexpression of MDM2 or MDM4, or by loss of upstream activators like ATM. Therapeutic strategies aim to restore p53 activity, for example by using MDM2 inhibitors or gene therapy. Understanding the regulation of p53 signaling (GO:1901796) is therefore critical for cancer treatment.
Inflammatory diseases
The crosstalk between p53 and NF-kB signaling has implications for inflammatory diseases and cancer. NF-kB is a master regulator of inflammation, and its interaction with p53 can influence the inflammatory microenvironment. Mycoplasma infections can modulate p53/NF-kB signaling, potentially contributing to chronic inflammation and cancer. Thus, targeting the regulation of p53 signal transduction may have therapeutic benefits in inflammatory conditions.
Neurodegeneration and neural stem cell regulation
p53 signaling plays a role in neural stem cell function and neuronal progenitor maintenance. Dysregulation of this pathway has been implicated in neurodegenerative diseases and aging. For example, altered p53 activity can affect neural stem cell self-renewal and differentiation, contributing to cognitive decline. Therefore, understanding GO:1901796 in the context of neural cells may reveal new therapeutic targets.
Ribosomopathies and developmental disorders
Ribosomal stress activates p53 through the nucleolar surveillance pathway, and mutations in ribosomal proteins can lead to ribosomopathies such as Diamond-Blackfan anemia. These disorders often involve p53-mediated cell cycle arrest and apoptosis, contributing to developmental defects. The regulation of p53 signal transduction is thus central to the pathophysiology of ribosomopathies.
From regulation of signal transduction by p53 class mediator-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate p53 stability? | Knockout of gene X in p53 wild-type cells, followed by p53 half-life analysis |
| Does a point mutation in TP53 affect its transcriptional activity? | Point mutation knock-in of TP53 in isogenic cell lines |
| Does gene Y interact with p53? | Knock-in of tagged p53 (e.g., GFP or HA) for co-immunoprecipitation |
| Does overexpression of gene Z activate p53 signaling? | Overexpression of gene Z in p53 reporter cells |
| Is gene W required for p53-mediated apoptosis? | Knockout of gene W followed by DNA damage treatment and apoptosis assay |
| Does a SNP in gene V alter p53 pathway regulation? | Knock-in of the SNP using CRISPR in relevant cell types |
How to Study the regulation of signal transduction by p53 class mediator Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify p53 target genes and pathway alterations |
| Proteomics (MS) | Protein interactions and modifications | Discover novel p53 regulators and post-translational modifications |
| Western blot | Protein levels and phosphorylation status | Assess p53 stabilization and activation |
| Luciferase reporter assay | Transcriptional activity of p53 | Screen for regulators of p53 signaling |
| Apoptosis assay (Annexin V) | Cell death | Evaluate p53-dependent apoptosis |
| Cell cycle analysis | DNA content and proliferation | Measure p53-mediated cell cycle arrest |
| Immunofluorescence | Subcellular localization | Study p53 nuclear import and nucleolar stress |
| CRISPR screening | Gene function in p53 pathway | Identify essential regulators of p53 signaling |
Transcriptomic profiling
RNA sequencing (RNA-seq) is widely used to measure changes in gene expression upon modulation of p53 signaling. By comparing wild-type and mutant cells, researchers can identify p53 target genes and assess the impact of regulatory factors. This method is essential for understanding the transcriptional output of GO:1901796.
Proteomic analysis
Mass spectrometry-based proteomics allows the identification of protein-protein interactions and post-translational modifications in the p53 pathway. For example, immunoprecipitation of p53 followed by mass spectrometry can reveal novel regulators. This approach helps map the complex regulatory network of p53 signal transduction.
Functional assays
Cell-based assays such as luciferase reporters for p53 activity, apoptosis assays (e.g., Annexin V staining), and cell cycle analysis are used to functionally validate the regulation of p53 signaling. These assays provide direct evidence of how a gene or treatment affects the pathway.
Imaging and localization studies
Fluorescence microscopy can visualize the subcellular localization of p53 and its regulators. For instance, nucleolar stress can be monitored by co-staining for nucleolar markers and p53. Live-cell imaging of p53 dynamics provides insights into the temporal regulation of signaling.
How CRISPR Can Be Used to Study GO:1901796 regulation of signal transduction by p53 class mediator
Knockout
CRISPR knockout is used to completely ablate genes involved in p53 signaling, such as TP53, MDM2, or CDKN1A, to study their roles in the regulation of signal transduction by p53 class mediator (GO:1901796). For example, knocking out MDM2 leads to p53 stabilization and activation, demonstrating its negative regulatory role. Knockout models are essential for determining the necessity of a gene in the pathway.
Point Mutation
Point mutations can be introduced into genes like TP53 to mimic cancer-associated mutations or to study specific phosphorylation sites. For instance, knock-in of the p53 Ser46 mutation can reveal its role in apoptosis versus cell cycle arrest. Point mutation models help dissect the precise molecular mechanisms of p53 regulation.
Knock-in
Knock-in of tagged versions of p53 (e.g., GFP-p53) allows for real-time tracking of protein localization and interactions. Additionally, knock-in of reporter genes under p53-responsive promoters enables monitoring of pathway activity. These models are valuable for studying the dynamics of p53 signaling in live cells.
Overexpression
Overexpression of wild-type or mutant p53, or of its regulators like MDM2, can be achieved via CRISPR activation (CRISPRa) or by introducing expression constructs. Overexpression studies help identify gain-of-function effects and are useful for screening potential therapeutic targets. For example, overexpression of MDM2 can suppress p53 activity, mimicking cancer-associated inactivation.
How EDITGENE Supports regulation of signal transduction by p53 class mediator Research
Researchers studying regulation of signal transduction by p53 class mediator-related genes often need to determine whether a candidate gene is causally involved in the pathway or is merely correlated with its activity. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such functional studies with high precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for regulation of signal transduction by p53 class mediator research.
Frequently Asked Questions About regulation of signal transduction by p53 class mediator
What is GO:1901796?
GO:1901796 is a Gene Ontology term for 'regulation of signal transduction by p53 class mediator', which encompasses any process that modulates the frequency, rate or extent of signal transduction by a p53 class mediator.
What genes are involved in regulation of signal transduction by p53 class mediator?
Key genes include TP53, MDM2, CDKN1A, BAX, NFKB1, ATM, CHEK2, and many others that regulate or are regulated by p53 signaling.
How is p53 signaling regulated?
p53 signaling is regulated by post-translational modifications, protein-protein interactions (e.g., with MDM2), and crosstalk with other pathways like NF-kB.
What diseases are associated with dysregulation of p53 signaling?
Dysregulation of p53 signaling is associated with cancer, inflammatory diseases, neurodegeneration, and ribosomopathies.
What research methods are used to study GO:1901796?
Common methods include CRISPR knockout, point mutation, knock-in, overexpression, RNA-seq, proteomics, and functional assays.
How does p53 regulate cell cycle and apoptosis?
p53 transcriptionally activates CDKN1A to induce cell cycle arrest and BAX to promote apoptosis, among other targets.
What is the role of NF-kB in p53 signaling?
NF-kB and p53 pathways exhibit crosstalk, with mutual regulation that influences inflammation, cell survival, and cancer.
Can CRISPR be used to study p53 signaling?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression are powerful tools to dissect the regulation of p53 signal transduction.
What are the therapeutic implications of targeting p53 signaling?
Targeting p53 signaling is a promising strategy for cancer therapy, with drugs like MDM2 inhibitors and gene therapy approaches under development.
How does ribosomal stress activate p53?
Ribosomal stress triggers the nucleolar surveillance pathway, leading to inhibition of MDM2 by ribosomal proteins like RPL5 and RPL11, thereby stabilizing p53.
Conclusion
GO:1901796, regulation of signal transduction by p53 class mediator, is a fundamental biological process that governs cellular responses to stress and is critical for maintaining genomic integrity. Its dysregulation is implicated in a wide range of diseases, particularly cancer, making it a prime target for therapeutic intervention. Advances in CRISPR-based models and high-throughput methods continue to unravel the complex regulatory networks of p53 signaling, offering new opportunities for drug discovery and personalized medicine. Researchers equipped with these tools and insights are well-positioned to translate basic findings into clinical applications.
References
- 1. Hoesel B et al.. 2013. The complexity of NF-κB signaling in inflammation and cancer.. Mol Cancer 12:86 PMID: 23915189
- 2. Leung AK et al.. 2010. MicroRNA functions in stress responses.. Mol Cell 40(2):205-15 PMID: 20965416
- 3. Borchsenius SN et al.. 2018. Effects of mycoplasma infection on the host organism response via p53/NF-κB signaling.. J Cell Physiol 234(1):171-180 PMID: 30146800
- 4. Hannan KM et al.. 2022. Nuclear stabilization of p53 requires a functional nucleolar surveillance pathway.. Cell Rep 41(5):111571 PMID: 36323262
- 5. Nguyen NMP et al.. 2025. AMH protects the ovary from doxorubicin by regulating cell fate and the response to DNA damage.. Proc Natl Acad Sci U S A 122(5):e2414734122 PMID: 39874288
- 6. Sun Y. 2006. p53 and its downstream proteins as molecular targets of cancer.. Mol Carcinog 45(6):409-15 PMID: 16652354
- 7. Zyuz'kov GN et al.. 2021. Specific Features of Intracellular Signal Transduction in the Regulation of Functions of Neural Stem Cells and Committed Neuronal Progenitors.. Bull Exp Biol Med 170(4):522-527 PMID: 33725249
- 8. Biswas P et al.. 2024. The experimental significance of isorhamnetin as an effective therapeutic option for cancer: A comprehensive analysis.. Biomed Pharmacother 176:116860 PMID: 38861855
